Cargando…
The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive to CGRP and CGRP Receptor Components in Rats
Treatment with the anti-CGRP antibody fremanezumab is successful in the prevention of chronic and frequent episodic migraine. In preclinical rat experiments, fremanezumab has been shown to reduce calcitonin gene-related peptide (CGRP) release from trigeminal tissues and aversive behaviour to noxious...
Autores principales: | Vogler, Birgit, Kuhn, Annette, Mackenzie, Kimberly D., Stratton, Jennifer, Dux, Mária, Messlinger, Karl |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487893/ https://www.ncbi.nlm.nih.gov/pubmed/37686275 http://dx.doi.org/10.3390/ijms241713471 |
Ejemplares similares
-
The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow
por: Dux, Mária, et al.
Publicado: (2022) -
Semi-Automated Recording of Facial Sensitivity in Rat Demonstrates Antinociceptive Effects of the Anti-CGRP Antibody Fremanezumab
por: Benedicter, Nicola, et al.
Publicado: (2023) -
CGRP outflow into jugular blood and cerebrospinal fluid and permeance for CGRP of rat dura mater
por: Risch, Miriam, et al.
Publicado: (2021) -
CGRP measurements in human plasma – a methodological study
por: Messlinger, Karl, et al.
Publicado: (2021) -
Changes in calcitonin gene-related peptide (CGRP) receptor component and nitric oxide receptor (sGC) immunoreactivity in rat trigeminal ganglion following glyceroltrinitrate pretreatment
por: Seiler, Kristin, et al.
Publicado: (2013)